



RON CHAPMAN, MD, MPH  
Director & State Health Officer

State of California—Health and Human Services Agency  
California Department of Public Health



EDMUND G. BROWN JR.  
Governor

OFFICE OF AIDS  
AIDS Drug Assistance Program (ADAP)

Management Memorandum  
Memorandum Number: 2014-10

Date: September 22, 2014

TO: LOCAL ADAP COORDINATORS  
ADAP ENROLLMENT WORKERS

SUBJECT: **ADDITION OF DOLUTEGRAVIR/LAMIVUDINE/ABACAVIR (TRIUMEQ)  
TO THE ADAP FORMULARY**

**Effective September 22, 2014**, dolutegravir (50mg)/lamivudine (300mg)/abacavir (600 mg) (Triumeq®) tablets have been added to the ADAP formulary.

Dolutegravir/lamivudine/abacavir is a new once-daily fixed dose combination antiretroviral (ARV) drug combining dolutegravir, an integrase strand transfer inhibitor (INSTI), with lamivudine and abacavir, both nucleoside reverse transcriptase inhibitors (NRTIs).

Dolutegravir/lamivudine/abacavir was approved by the federal Food and Drug Administration on August 22, 2014 for use in individuals infected with the human immunodeficiency virus (HIV). Each of the separate ARV components of this new combination drug is already on the ADAP formulary.

With the addition of dolutegravir/lamivudine/abacavir, ADAP has 188 drugs on the formulary.

If you have any questions regarding the addition of this new ARV medication to the ADAP formulary, please contact me at (916) 449-5943.

Celia Banda-Brown, Chief  
ADAP Section  
Office of AIDS